Chemomab Therapeutics Ltd... (CMMB)
NASDAQ: CMMB
· Real-Time Price · USD
3.38
-0.07 (-2.03%)
At close: Oct 15, 2025, 3:59 PM
3.39
0.30%
After-hours: Oct 15, 2025, 06:12 PM EDT
Chemomab Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | n/a | n/a |
Cost of Revenue | 53.25K | 66.83K | 57.77K | 34.02K |
Gross Profit | -53.25K | -66.83K | -57.77K | -34.02K |
Operating Income | -14.74M | -25.46M | -28.53M | -12.37M |
Interest Income | 797.77K | 1.24M | 351.62K | 65.00 |
Pretax Income | -13.95M | -24.22M | -28.18M | -12.48M |
Net Income | -13.95M | -24.22M | -27.65M | -12.48M |
Selling & General & Admin | 3.41K | 7.08M | 11.56M | 6.03M |
Research & Development | 11.33K | 18.38M | 16.98M | 6.33M |
Other Expenses | 14.72M | n/a | n/a | n/a |
Operating Expenses | 14.74M | 25.46M | 28.53M | 12.37M |
Interest Expense | n/a | n/a | 353K | 111.08K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 14.74M | 25.46M | 28.53M | 12.37M |
Income Tax Expense | n/a | n/a | -534K | n/a |
Shares Outstanding (Basic) | 17.95M | 11.75M | 11.38M | 10.37M |
Shares Outstanding (Diluted) | 17.95M | 11.75M | 11.38M | 10.37M |
EPS (Basic) | -0.78 | -2 | -2.4 | -1.2 |
EPS (Diluted) | -0.78 | -2 | -2.4 | -1.2 |
EBITDA | -13.96M | -25.39M | -28.48M | -12.33M |
EBIT | -14.01M | -25.46M | -28.53M | -12.37M |
Depreciation & Amortization | 53.25K | 67K | 57.77K | 34.02K |
Source: Financial Modeling Prep. Financial Sources.